Radius Health, Inc.
NasdaqGS RDUS
Radius Health, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -12.31
-
Radius Health, Inc. 52-week high Price to Earnings Ratio (P/E) is -11.88 on January 10, 2025, which is 3.44% above the current Price to Earnings Ratio (P/E).
-
Radius Health, Inc. 52-week low Price to Earnings Ratio (P/E) is -29.34 on January 30, 2024, which is -138.38% below the current Price to Earnings Ratio (P/E).
-
Radius Health, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -19.60.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Ms. Tamara L. Lundgren J.D. |
| IPO Date | June 6, 2014 |
| Location | United States |
| Headquarters | 950 Winter St |
| Employees | 3,011 |
| Sector | Health Care |
| Industries | |
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email